Loading asset research
SELLAS Life Sciences Group Inc. Common Stock
SLSNasdaq · USD · StocksQuote as of · Exchange session not verified$11.55
-14.42%
Today
SLS
Loading 1D prices…
Market cap
$2.3B
Volume
14.6M
52w high
$15.8852w low
$1.39Company profile
SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
New York, NY, United States
Employees
13
Fiscal year end
1231
CIK
1390478
Session & valuation
Open$13.55
Previous close$13.49
Day high$13.74
Day low$11.38
30-day avg. volume6.9M
Outstanding shares201.9M
Diluted EPS-$0.25
Latest annual period
P/E (trailing)-46.18
P/E (forward)-115.45
Price / book16.93
Beta2.52
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| OCULOcular Therapeutix Inc. Common Stock | $2.3B | $52M | -511.90% | -$1.42 | -1.18% | Buy |
| NKTRNektar Therapeutics Common Stock | $2.4B | $55.2M | -296.93% | -$9.73 | -1.25% | Buy |
| BRVEBraveheart Bio Inc. Common Stock | $2.4B | $0.00 | — | -$5.32 | -2.02% | Buy |
| TRVITrevi Therapeutics Inc. Common Stock | $2.3B | $0.00 | — | -$0.32 | +0.06% | Buy |
| VRDNViridian Therapeutics Inc. Common Stock | $2.4B | $70.8M | -483.56% | -$3.32 | -4.76% | Buy |